MARKET

ILMN

ILMN

Illumina Inc
NASDAQ
137.32
-1.36
-0.98%
After Hours: 137.50 +0.18 +0.13% 19:24 03/28 EDT
OPEN
138.68
PREV CLOSE
138.68
HIGH
140.07
LOW
136.29
VOLUME
917.08K
TURNOVER
0
52 WEEK HIGH
233.42
52 WEEK LOW
89.00
MARKET CAP
21.82B
P/E (TTM)
-18.6878
1D
5D
1M
3M
1Y
5Y
Catalyst Watch: Tesla deliveries, Disney board vote, DJT drama and Fortinet event
Volatility watch - Options trading volume is elevated on Trump Media & Technology (DJT) Key data reports due to arrive this week include updates on Tesla deliveries, Disney board vote, and Solventum spin-off. Fortinet will hold its four-day Accelerate 2024 event in New York.
Seeking Alpha · 12h ago
May 10th Options Now Available For Illumina (ILMN)
NASDAQ · 15h ago
GRAIL Presents New Data On Galleri And Its Methylation Platform At The Annual American Association For Cancer Research Meeting
New Data Will Highlight Use of GRAIL's Targeted Methylation Platform across Early Cancer Detection and Precision Oncology at the American Association for Cancer Research Annual Meeting in San Diego, 2024. Longer-term data Underscore the Potential Value of Galleri for Repeat Screening for Clinically Significant Cancers. GRAil will present new data on the impact of multi-cancer early detection testing in guiding diagnostic evaluation.
Benzinga · 1d ago
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
NASDAQ · 2d ago
Weekly Report: what happened at ILMN last week (0318-0322)?
Weekly Report · 3d ago
Illumina’s Stock Rating Maintained at Hold Amid Legal Uncertainties and Regulatory Challenges
TipRanks · 6d ago
Why Illumina Stock Zoomed Higher on Thursday
Gene-sequencing specialist Illumina's share price rose over 3% on Thursday. A European Commission advisor criticized the Commission's ruling on an Illumina acquisition. The company's $8 billion deal to purchase cancer detection company Grail was blocked in 2021. The European Commission says the ruling should be annulled.
The Motley Fool · 03/21 22:37
EU Antitrust Regulators Overstepped in Illumina-Grail Deal, Says Court Adviser
EU antitrust regulators blocked Illumina's $7.1 billion bid for Grail Inc. An adviser to Europe's top court says the EU exceeded their powers in blocking the deal. The adviser's opinion could impact other merger deals in the future, including one involving Qualcomm Inc.
Benzinga · 03/21 17:56
More
About ILMN
Illumina, Inc. is a provider of sequencing- and array-based solutions for genetic and genomic analysis. The Company operates through two segments: Core Illumina and GRAIL. Its Core Illumina segment offers products and services that serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. Its GRAIL segment is a healthcare company focused on early detection of multiple cancers. Its portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed to accelerate and simplify genetic analysis. Its BaseSpace Informatics Suite integrates directly with its sequencing instruments, allowing customers to manage their biological sample and sequencing runs, process and analyze the raw genomic data, and derive results. Its BeadArray technology combines microscopic beads and a substrate in a proprietary manufacturing process to produce arrays that can perform various assays simultaneously.

Webull offers Illumina Inc stock information, including NASDAQ: ILMN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ILMN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ILMN stock methods without spending real money on the virtual paper trading platform.